Table 2 Clinical data of 28 patients with SFT
From: Solitary fibrous tumor – clinicopathologic, immunohistochemical and molecular analysis of 28 cases
Case | Age | Sex | Size (cm) | Site | Margin status | Treatment | Local recurrence | MET | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
1 | 21 | F | 9 | Abdomen | Neg | SE | Y, multiple | Y | DOD, 52 yrs |
2 | 74 | F | 9 | Calf | Neg | SE | NA | NA | NA |
3 | 59 | M | 13 | Pelvis | Neg | SE; CT after MET | Y | Y | NED, MET 48 mo |
4 | 55 | F | 9.5 | Retro-peritoneum | Neg | SE; CT + RT after MET | N | Y | DOD, 13 mo |
5 | 84 | F | 10 | Para-tracheal | Neg | SE | NA | NA | NED, 48 mo |
6 | 68 | F | 17 | Lung | Neg | SE | NA | NA | NA |
7 | 39 | F | 3 | Thigh | Neg | SE | N | N | NED, 36 mo |
8 | 34 | M | 4.1 | Cheek | Neg | SE | N | N | NED, 27 mo |
9 | 75 | F | 12 | Neck | Neg | SE | N | N | NED, 26 mo |
10 | 50 | F | 10 | Uterus | Neg | SE | N | N | NED, 33 mo |
11 | 52 | F | 4.7 | Biceps | Neg | SE | N | N | NED, 32 mo |
12 | 52 | M | 6.3 | Lung | Pos | SE | N | N | NED, 17 mo |
13 | 56 | M | 16 | Pelvis | Neg | SE | N | N | NED, 12 mo |
14 | 53 | F | 4.5 | Pleura | Neg | SE | N | N | NED, 21 mo |
15 | 71 | M | NA | Lung | NA | SE | NA | NA | NA |
16 | 39 | M | 2 | Mastoid | Pos | EMB + SE; SE + RT after recurrence | Y | N | NED, 7 mo after treatment of recurrent disease |
17 | 44 | F | 2.5 | Orbit | Neg | SE | Y | N | NA |
18 | 55 | M | 13 | Lung | Neg | SE | N | N | NED, 9 yrs |
19 | 63 | M | 4 | Lung | Neg | SE | NA | NA | NA |
20 | 45 | F | 7.5 | Mesenterium | Neg | SE | N | N | NED, 10 yrs |
21 | 33 | F | 9 | Calf | Pos | SE | N | N | NED, 23 mo |
22 | 67 | F | NA | Buttock | NA | SE | N | N | NA |
23 | 68 | F | 14 | Pleura | NA | SE | N | N | NED, 8 mo |
24 | 76 | M | 7 | Abdomen | Neg | SE | NA | NA | NA |
25 | 69 | F | NA | Lung | NA | SE | NA | NA | NA |
26 | 43 | M | 9.5 | Back | Neg | SE | NA | NA | NA |
27 | 42 | F | 1.6 | Head | Neg | SE | NA | NA | NA |
28 | 42 | F | 5.5 | Knee | Neg | SE | N | N | NED, 9 yrs |